Reslizumab

Reslizumab?
Monoclonal antibody
Type Whole antibody
Source Humanized (from rat)
Target IL-5
Clinical data
Identifiers
 Yes
None
Chemical data
 Yes (what is this?)  (verify)

Reslizumab is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways, skin and gastrointestinal tract.[1] As of September 2009, the drug is undergoing Phase II/III clinical trials.[2]

References

  1. ↑ Walsh, GM (2009). "Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions". Current opinion in molecular therapeutics 11 (3): 329–36. PMID 19479666.
  2. ↑ ClinicalTrials.gov